

EUnetHTA

European Network for Health Technology Assessment

Joint Action 3 | 2016-2021

Legal basis

Directive 2011/24/EU on cross-border healthcare



The Directive provides a detailed legal framework focused on:

Rules concerning the reimbursement of cross-border healthcare costs.

Cross-border healthcare responsibilities of Member States.

Cooperation between healthcare systems.



EU objectives in HTA Article 15, Directive 2011/24:


Support cooperation between national HTA authorities.

Support Member States in the provision of objective, reliable, timely, transparent, comparable and transferable information [...] to enable effective exchange of information.

Avoid duplication of assessments.



The history of EUnetHTA



Specific objectives of Joint Action 3



To increase production of **high quality** HTA joint work.



To increase **uptake** and **implementation** of joint HTA work at the **national, regional and local level**.



To support **evidence-based, sustainable and equitable choices** in healthcare and health technologies.

Governance



Governance continued

Members of the EUnetHTA Executive Board (and countries represented in the Heads of Agencies)



Governance continued



Niklas Hedberg

Chair of the Executive Board
Chief Pharmaceutical Officer at
TLV, Sweden



Chantal Bélorgey

Vice-Chair of the Executive Board
Head of HTA and Public Health at
HAS, France



Zoe Garrett

Vice-Chair of the Executive Board
Senior Technical Advisor at
NICE, UK

Transversal groups

GROUP TITLE		CHAIR
Future Model of Cooperation on HTA	FMC-HTA	Marcus Guardian, ZIN (Netherlands)
Conflict of Interest	COI	Giovanni Tafuri, ZIN (Netherlands)
Patients, Consumers, and Healthcare Providers	P&C/HCP	Giovanni Tafuri, ZIN (Netherlands)
HTA and MDR/IVDR - Medical Devices	-	Claudia Wild, LBI-HTA (Austria)
EUnetHTA Common Phrases	ECP	Rudy Dupree, ZIN (Netherlands)
HTA Core Model	-	IQWiG (Germany)
Task Identification and Prioritisation Group	TISP	Vigdis Lauvrak, NIPHNO (Norway)

Financing of EUnetHTA JA3

€20M

Total project budget

60/40

This is made up of
60% EU funding and
40% Member State
contribution






83+ partners from more
than **30** countries from
across Europe

These consist of national, regional and non-for-profit agencies that produce or contribute to HTA.

Disclaimer: The designations employed and the presentation of the material on this map do not imply the expression of any opinion whatsoever on the part of EUnethHTA concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries.

Every effort is made to ensure this map is free of errors but there is no warrant the map or its features are either spatially or temporally accurate or fit for a particular use. This map is provided without any warranty of any kind whatsoever, either express or implied.

Our partners



Our original key products



Early Dialogues




Joint Assessments



Post Launch
Evidence Generation

Product lifecycle elements | Pharmaceuticals



EUnetHTA productions in numbers so far (pharma and other technologies)

18

Joint
Assessments
on Pharma

27

Collaborative
(25) and Joint
(2) Assessments
on Other
Technologies

34

Early
Dialogues
(1 MD)
+ 5 ongoing

5


Post Launch
Evidence
Generation
pilots

18


Covid-19-related assessments. This is made up of:
15 PT Rolling Collaborative Reviews
2 OT Rapid Collaborative Reviews
1 PT Rapid Collaborative Review

As of October 2020

Setting



Governance



Key achievements



Secure collaborative working space & communication platforms.




The EUnetHTA Prioritisation List (EPL).



Large and growing partner base and recognition as a one-stop-shop for HTA in Europe.



Joint Production of Assessments, Scientific Advice, PLEG, Methodology



Streamlined governance structure.



Strong collaboration with key stakeholders



Significant interest from developing HTA agencies for support and guidance.

Where next?



Continued focus on the production of Joint Assessments and Early Dialogues.



Continued refinement of processes and procedures.



Development of a future model of cooperation on HTA.



Working to meet the project's deliverables and milestones.

Thank you

For more information, email eunethta@zinl.nl